The diagnosis and management of hypercalcaemia

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Minisola, Salvatore ^a   Pepe, Jessica ^a   Piemonte, Sara ^a   Cipriani, Cristiana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CINACALCET; CLODRONIC ACID; CREATININE; DENOSUMAB; FUROSEMIDE; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; THIAZIDE DIURETIC AGENT; ZOLEDRONIC ACID; LOOP DIURETIC AGENT;

ACUTE KIDNEY FAILURE; AGE DISTRIBUTION; CALCIUM BLOOD LEVEL; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG ACTIVITY; FEVER; HEMODIALYSIS; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERTHYROIDISM; HYPOCALCEMIA; INCIDENCE; INFUSION RELATED REACTION; MYALGIA; NAUSEA; PARANEOPLASTIC SYNDROME; PREVALENCE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; REHYDRATION; REVIEW; RHABDOMYOLYSIS; SEX DIFFERENCE; TREATMENT DURATION; COMPLICATION; ENDOCRINE DISEASE; NEOPLASM; PARATHYROID DISEASE; PHYSIOLOGY; PROCEDURES; RENAL REPLACEMENT THERAPY;

ACUTE KIDNEY INJURY; DIPHOSPHONATES; ENDOCRINE SYSTEM DISEASES; HUMANS; HYPERCALCEMIA; NEOPLASMS; PARATHYROID DISEASES; PARATHYROID HORMONE; RENAL DIALYSIS; SODIUM CHLORIDE SYMPORTER INHIBITORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 84936984888     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h2723     Document Type: Review

References (34)

1. Dalemo S, Eggertsen R, Hjerpe P, et al. Long-term follow-up of patients with elevated serum calcium concentrations in Swedish primary care. Scand J Prim Health Care 2012;30:48-54.
2. Lindner G, Felber R, Schwarz C, et al. Hypercalcemia in the ED: prevalence, etiology, and outcome. Am J Emerg Med 2013;31:657-60.
3. National Cancer Institute. PDQ® Hypercalcemia. 2013. www.meb.uni-bonn.de/Cancernet/CDR0000062737.html.
4. Potts JT Jr, Jüppner H. Disorders of the parathyroid gland and calcium homeostasis. In: Longo DL, Fauci AS, Kasper DL, Hauser S, eds. Harrison's principles of internal medicine. 18th ed. McGraw-Hill, 2012:3096-120.
5. Yu N, Donnan PT, Murphy MJ, et al. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol 2009;71:485-93.
6. Wermers RA, Khosla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006;21:171-7.
7. Yeh MW, Ituarte PH, Zhou HC, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 2013;98:1122-9.
8. Gastanaga V, Jain R, Pirolli M, et al. Prevalence of hypercalcemia of malignancy in the United States. Projection methods using oncology electronic health records. Eur J Cancer 2013;49:S302-3.
9. McKay C, Furman WL. Hypercalcemia complicating childhood malignancies. Cancer 1993;72:256-60.
10. Horwitz MJ, Hodak SP, Stewart AF. Non-parathyroid hypercalcemia. In: Rosen CJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 8th ed. Wiley-Blackwell, 2013:562-71.
11. Grieff M, Bushinsky DA. Diuretics and disorders of calcium homeostasis. Semin Nephrol 2011;31:535-41.
12. Wermers RA, Kearns AE, Jenkins GD, et al. Incidence and clinical spectrum of thiazide-associated hypercalcemia. Am J Med 2007;120:911.e9-15.
13. Kohut B, Rossat J, Raffoul W, et al. Hypercalcaemia and acute renal failure after major burns: An under-diagnosed condition. Burns 2010;36:360-6.
14. Sato Y, Honda Y, Iwamoto J, et al. Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients. Mov Disord 2005;20:1598-603.
15. Carnevale V, Dionisi S, Nofroni I, et al. Potential clinical utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism. Clin Chem 2004;50:626-31.
16. Eastell R, Brandi ML, Costa AG, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab 2014;99:3570-9.
17. Marcocci C, Bollerslev J, Khan AA, et al. Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab 2014;99:3607-18.
18. Minisola S, Romagnoli E, Scillitani A, et al. Hypovitaminosis D in primary hyperparathyroidism: to treat or not to treat? That is the question. J Endocrinol Invest 2014;37:413-4.
19. Streeten EA, Jaimungal S. The differential diagnosis of hypercalcemia. The parathyroids. 3rd ed. Academic Press, 2014:607-16.
20. Minisola S, Romagnoli E, Scarnecchia L, et al. Parathyroid storm: immediate recognition and pathophysiological considerations. Bone 1993;14:703-6.
21. Dionisi S, Minisola S, Pepe J, et al. Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type 1: presentation as hypercalcemic crisis. Mayo Clin Proc 2002;77:866-9.
22. Lowe H, Cusano NE, Binkley N, et al. Vitamin D toxicity due to a commonly available "over the counter" remedy from the Dominican Republic. J Clin Endocrinol Metab 2011;96:291-5.
23. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3561-9.
24. Silverberg SJ, Clarke BL, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3580-94.
25. Schwarz P, Body JJ, Cap J, et al. The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice. Eur J Endocrinol 2014;171:727-35.
26. Minisola S, Romagnoli E, Carnevale V, et al. Acute management of hypercalcemia. In: Bilezikian JP, Marcus R, Levine M, Marcocci, C, Silverberg SJ, Potts J, eds. Parathyroids, basic and clinical concepts. 3rd ed. Academic Press, 2014:617-29.
27. LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med 2008;149:259-63.
28. Kawada K, Minami H, Okabe K, et al. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy. Jpn J Clin Oncol 2005;35:28-33.
29. Purohit OP, Radstone CR, Anthony C, et al. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 1995;72:1289-93.
30. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-67.
31. Roemer-Bécuwe C, Vigano A, Romano F, et al. Safety of subcutaneous clodronate and efficacy in hypercalcemia of malignancy: a novel route of administration. J Pain Symptom Manage 2003;26:843-8.
32. Reagan P, Pani A, Rosner MH. Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy. Am J Kidney Dis 2014;63:141-7.
33. Hu MI, Glezerman IG, Leboulleux S, et al. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab 2014;99:3144-52.
34. Kindgen-Milles D, Kram R, Kleinekofort W, et al. Treatment of severe hypercalcemia using continuous renal replacement therapy with regionalcitrate anticoagulation. ASAIO J 2008;54:442-4.